Long Read Analysis in Spinal Muscular Atrophy - LOREASI

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Rouen

About this trial

Spinal Muscular Atrophy (SMA) is a severe neuromuscular disease caused by deletion of the SMN1 gene, with the most severe form leading to death in children without treatment. Genetic counselling to detect couples where both partners are carriers is particularly important. In some countries, preconception screening is offered. However, some carriers escape detection due to the existence of two copies of the SMN1 gene side-by-side (2+0 genotype). Currently, no molecular genetic methods used for diagnostic purposes can detect these 2+0 genotypes, which pose a significant challenge in genetic counselling.

This study aims to use new technologies based on the analysis of ultra-long molecules to detect side-by-side duplications of the SMN1 gene to detect heterozygous subjects not identified by current techniques and improve genetic counselling.

Eligibility criteria

Qualifiers

1 or 3 copies of the SMN1 gene (control group) and a variable number of copies of the SMN2 gene

2 copies of the SMN1 gene in cis (2+0 genotype) (test group)

Affiliation to French health insurance

Signed consent form

Disqualifiers

Pregnant or breastfeeding women

Individuals deprived of liberty by an administrative or judicial decision, or those under guardianship or curatorship

Trial design

Treatments tested in this trial

  • blood sample

Treatment groups

27 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University Hospital, Rouen

Lead sponsor

Agence de La Biomédecine

Collaborator